AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23777776 — intervention group
Group type: EXPERIMENTAL
Intervention: Resident-initiated advanced triage
Number of subjects: 1346
Study 23777776 — intervention group
Group type: COMPARATOR
Intervention: Control (patients evaluated during the 6-h period on other weekdays)
Number of subjects: 1346
Study 21570522 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/d n3-PUFA
Number of subjects: 43
Study 21570522 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/d n3-PUFA
Number of subjects: 43
Study 21570522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 19770175 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy home program (OTHP) for 8 weeks
Number of subjects: 36
Study 19770175 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy home program (OTHP) for 4 weeks (continued for 8 weeks)
Number of subjects: 36
Study 19770175 — intervention group
Group type: COMPARATOR
Intervention: No occupational therapy home program (no OTHP)
Number of subjects: 36
Study 17623345 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline viral load level
Number of subjects: 0
Study 17623345 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+ cell counts
Number of subjects: 0
Study 17623345 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8 cell counts
Number of subjects: 0
Study 17623345 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's age
Number of subjects: 0
Study 15580811 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C, 800 mg vitamin E, and 10 mg folate
Number of subjects: 31
Study 15580811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 11797982 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rtPA)
Number of subjects: 234
Study 11797982 — intervention group
Group type: COMPARATOR
Intervention: Urokinase (UK)
Number of subjects: 234
Study 11797982 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rtPA and UK (independent of delivery technique)
Number of subjects: 234
Study 9740162 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at 0.2 IU/kg/d subcutaneously for 4 weeks
Number of subjects: 17
Study 9740162 — intervention group
Group type: COMPARATOR
Intervention: Control group (dietary prescriptions only)
Number of subjects: 17
Study 7989939 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (adjuvant fluorouracil (5-FU)-based)
Number of subjects: 294
Study 7989939 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 294
Study 7989939 — intervention group
Group type: COMPARATOR
Intervention: Low TS levels (no specific intervention mentioned)
Number of subjects: 294
Study 2925972 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive interactional context
Number of subjects: 0
Study 2925972 — intervention group
Group type: COMPARATOR
Intervention: Negative interactional context
Number of subjects: 0
Study 2925972 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissatisfied set
Number of subjects: 0
Study 2925972 — intervention group
Group type: COMPARATOR
Intervention: Satisfied set
Number of subjects: 0
Study 2925972 — intervention group
Group type: EXPERIMENTAL
Intervention: Established negative sets regarding adolescent's behaviors
Number of subjects: 0
Study 31999946 — intervention group
Group type: COMPARATOR
Intervention: TAS-102
Number of subjects: 93
Study 31999946 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-102 plus bevacizumab
Number of subjects: 93
Study 30997744 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction cards
Number of subjects: 60
Study 30997744 — intervention group
Group type: COMPARATOR
Intervention: Control (family nearby, no distraction techniques)
Number of subjects: 60
Study 28314744 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 140
Study 28314744 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 140
Study 25533572 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 104
Study 25533572 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block (SGB)
Number of subjects: 104
Study 25533572 — intervention group
Group type: COMPARATOR
Intervention: Follow-up observation (no treatment)
Number of subjects: 104
Study 22959395 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose multidetector computed tomography coronary angiography (MDCT)
Number of subjects: 80
Study 22959395 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 80
Study 21982664 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib (ANA) 150 mg
Number of subjects: 589
Study 21982664 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib (ANA) 300 mg
Number of subjects: 589
Study 21982664 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib (ANA) 40 mg
Number of subjects: 589
Study 21982664 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (ATV) 20 mg with Anacetrapib
Number of subjects: 589
Study 18652550 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal trivalent inactivated influenza vaccine (15 or 21 microg of hemagglutinin per strain)
Number of subjects: 1107
Study 18652550 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular control vaccine
Number of subjects: 1107
Study 16582061 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg daily)
Number of subjects: 533
Study 16582061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 533
Study 12709465 — intervention group
Group type: EXPERIMENTAL
Intervention: COER verapamil (180 mg)
Number of subjects: 16602
Study 12709465 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg) or Hydrochlorothiazide (12.5 mg)
Number of subjects: 16602
Study 12709465 — intervention group
Group type: EXPERIMENTAL
Intervention: COER verapamil
Number of subjects: 16602
Study 12709465 — intervention group
Group type: COMPARATOR
Intervention: Atenolol or Hydrochlorothiazide
Number of subjects: 16602
Study 12709465 — intervention group
Group type: EXPERIMENTAL
Intervention: Any prespecified cardiovascular disease-related event
Number of subjects: 16602
Study 12709465 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 16602
Study 11044869 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 117
Study 8642189 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 133
Study 8642189 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 133
Study 8642189 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 133
Study 8642189 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 133
Study 8642189 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 133
Study 1421641 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 140
Study 1421641 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 140
Study 3003298 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CAP) 25 mg orally
Number of subjects: 6
Study 3003298 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CAP) + Naloxone (NAL) 0.4 mg bolus followed by 4.0 mg/h infusion
Number of subjects: 6
Study 3003298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 6
Study 3003298 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (NAL)
Number of subjects: 6
Study 3003298 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CAP)
Number of subjects: 6
Study 31510831 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural and general anesthesia
Number of subjects: 0
Study 31510831 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 0
Study 29045820 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream
Number of subjects: 601
Study 29045820 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil cream
Number of subjects: 601
Study 29045820 — intervention group
Group type: COMPARATOR
Intervention: methyl aminolevulinate photodynamic therapy (MAL-PDT)
Number of subjects: 601
Study 26718237 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy plus medication
Number of subjects: 50
Study 26718237 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 24317794 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 24317794 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 0
Study 24317794 — intervention group
Group type: COMPARATOR
Intervention: Baseline triacylglycerol concentrations
Number of subjects: 0
Study 24317794 — intervention group
Group type: COMPARATOR
Intervention: Baseline BMI
Number of subjects: 0
Study 24317794 — intervention group
Group type: COMPARATOR
Intervention: Baseline visceral adiposity
Number of subjects: 0
Study 24317794 — intervention group
Group type: COMPARATOR
Intervention: Baseline subcutaneous adiposity
Number of subjects: 0
Study 24317794 — intervention group
Group type: EXPERIMENTAL
Intervention: Gly482Ser (rs8192678, PPARGC1A)
Number of subjects: 0
Study 23090987 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (100-200 mg daily) + CCNU (90-110 mg/m2)
Number of subjects: 26
Study 23090987 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib + CCNU
Number of subjects: 26
Study 20606413 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous erythropoietin receptor activator (CERA) once monthly
Number of subjects: 0
Study 20606413 — intervention group
Group type: COMPARATOR
Intervention: Epoetin beta therapy
Number of subjects: 0
Study 17629056 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopy
Number of subjects: 522
Study 17629056 — intervention group
Group type: COMPARATOR
Intervention: Active observation
Number of subjects: 522
Study 15865068 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin on day 1 followed by paclitaxel on day 2 (sequence A)
Number of subjects: 46
Study 15865068 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel on day 1 followed by epirubicin on day 2 (sequence B)
Number of subjects: 46
Study 12065998 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent visual analogue scale (VAS) ratings
Number of subjects: 78
Study 12065998 — intervention group
Group type: EXPERIMENTAL
Intervention: Child visual analogue scale (VAS) ratings
Number of subjects: 78
Study 9797618 — intervention group
Group type: EXPERIMENTAL
Intervention: Portage (developmental education programme)
Number of subjects: 309
Study 9797618 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent adviser (nondirectional counselling)
Number of subjects: 309
Study 9797618 — intervention group
Group type: COMPARATOR
Intervention: Preterm control
Number of subjects: 309
Study 7644052 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg qid)
Number of subjects: 16
Study 7644052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2693431 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized pharmacokinetic (PK) dosing of amikacin
Number of subjects: 82
Study 2693431 — intervention group
Group type: COMPARATOR
Intervention: Standard (every 12 h) dosing of amikacin
Number of subjects: 82
Study 681132 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg thioridazine
Number of subjects: 20
Study 681132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30785496 — intervention group
Group type: EXPERIMENTAL
Intervention: Oregano essential oil (OEO) at 150 mg.kg‐1
Number of subjects: 240
Study 30785496 — intervention group
Group type: EXPERIMENTAL
Intervention: Oregano essential oil (OEO) at 200 mg.kg‐1
Number of subjects: 240
Study 30785496 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (CT) with zinc bacitracin
Number of subjects: 240
Study 29392288 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg)
Number of subjects: 546
Study 29392288 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 546
Study 29392288 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg)
Number of subjects: 546
Study 25731901 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 200 mg
Number of subjects: 171
Study 25731901 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 400 mg
Number of subjects: 171
Study 25731901 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 200 mg (2 doses)
Number of subjects: 171
Study 25731901 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 400 mg (2 doses)
Number of subjects: 171
Study 25731901 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no NAC)
Number of subjects: 171
Study 24327455 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled 'no-touch' (NT) technique
Number of subjects: 17
Study 24327455 — intervention group
Group type: COMPARATOR
Intervention: Conventional (CON) technique
Number of subjects: 17
Study 22950861 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (10 mg/kg once a day for the first 3 days of life) with moderate hypothermia
Number of subjects: 64
Study 22950861 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with moderate hypothermia alone
Number of subjects: 64
Study 21058473 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF plus acupuncture (A)
Number of subjects: 86
Study 21058473 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF
Number of subjects: 86
Study 17558118 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril +/‐ indapamide
Number of subjects: 298
Study 16306522 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (nonselective beta-blocker)
Number of subjects: 213
Study 16306522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 11989511 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume exercise rehabilitation
Number of subjects: 2
Study 11989511 — intervention group
Group type: COMPARATOR
Intervention: Normal activity
Number of subjects: 2
Study 10096387 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride treatment for 24 to 30 months
Number of subjects: 19
Study 7674643 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 16
Study 7674643 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 16
Study 7674643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2291868 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5, 25 and 50 mg)
Number of subjects: 14
Study 2291868 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam (15 mg)
Number of subjects: 14
Study 2291868 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg)
Number of subjects: 14
Study 7316551 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical exothermic pads (hyperthermia)
Number of subjects: 22
Study 7316551 — intervention group
Group type: COMPARATOR
Intervention: Goeckerman's regimen (control)
Number of subjects: 22
Study 7316551 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia and Goeckerman's regimen (combined)
Number of subjects: 22
Study 31112385 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg
Number of subjects: 0
Study 31112385 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg
Number of subjects: 0
Study 31112385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31112385 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 10 mg
Number of subjects: 0
Study 31112385 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg (TERRANOVA)
Number of subjects: 0
Study 31112385 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg (TERRANOVA)
Number of subjects: 0
Study 31112385 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TERRANOVA)
Number of subjects: 0
Study 28875371 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin group (heparin bolus 70 IU per kg body weight before PA catheter insertion)
Number of subjects: 60
Study 28875371 — intervention group
Group type: COMPARATOR
Intervention: Control group (pretreatment with placebo)
Number of subjects: 60
Study 26527466 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise + BFR
Number of subjects: 28
Study 26527466 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise only
Number of subjects: 28
Study 26527466 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 24447181 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting echocardiographic optimization of CRT (AV delay plus VV delay)
Number of subjects: 59
Study 24447181 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting echocardiographic optimization
Number of subjects: 59
Study 24447181 — intervention group
Group type: COMPARATOR
Intervention: Exercise echocardiographic optimization
Number of subjects: 59
Study 24447181 — intervention group
Group type: COMPARATOR
Intervention: No optimization
Number of subjects: 59
Study 21573917 — intervention group
Group type: EXPERIMENTAL
Intervention: Bursectomy
Number of subjects: 210
Study 21573917 — intervention group
Group type: COMPARATOR
Intervention: Non-bursectomy
Number of subjects: 210
Study 19909743 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% mannitol meal (350 mL)
Number of subjects: 54
Study 19909743 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose meal (350 mL)
Number of subjects: 54
Study 19909743 — intervention group
Group type: EXPERIMENTAL
Intervention: 331-kcal meal with bran
Number of subjects: 54
Study 19909743 — intervention group
Group type: COMPARATOR
Intervention: 331-kcal meal without bran
Number of subjects: 54
Study 19909743 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-D diet with bran meal
Number of subjects: 54
Study 19909743 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-D patients
Number of subjects: 54
Study 17505641 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial revascularization procedures
Number of subjects: 0
Study 17505641 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0
Study 17505641 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive control of glycemic levels, strict management of all conventional risk factors, and lifestyle modification
Number of subjects: 0
Study 17505641 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitizers
Number of subjects: 0
Study 17505641 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapeutic modalities
Number of subjects: 0
Study 15636619 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive standard (IFN) or pegylated (peg-IFN) interferon alfa-2b (3 MU thrice weekly or 1.5 microg/kg weekly) plus ribavirin (600 mg increased to 1.0-1.2 g daily) initiated 2-6 weeks post-transplantation for 48 weeks
Number of subjects: 124
Study 15636619 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (IFN/peg-IFN plus ribavirin)
Number of subjects: 124
Study 15636619 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth factor (GF) use (erythropoietin and GCSF)
Number of subjects: 124
Study 12132563 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gemifloxacin
Number of subjects: 438
Study 12132563 — intervention group
Group type: COMPARATOR
Intervention: Oral clarithromycin
Number of subjects: 438
Study 10212514 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (700 mg oral for 5 days)
Number of subjects: 137
Study 10212514 — intervention group
Group type: COMPARATOR
Intervention: Quinine + tetracycline (7-day regimen)
Number of subjects: 137
Study 7790130 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived risk of infection
Number of subjects: 0
Study 7790130 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV knowledge
Number of subjects: 0
Study 7790130 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived susceptibility to HIV
Number of subjects: 0
Study 7790130 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived peer norms regarding drug-related risk reduction
Number of subjects: 0
Study 2127095 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative Care (CC) program
Number of subjects: 0
Study 7005645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (cyclophosphamide 200 mg/m2 IV weekly x 4 and Adriamycin 40 mg/m2 IV weeks 1 and 3)
Number of subjects: 54
Study 7005645 — intervention group
Group type: COMPARATOR
Intervention: No intensive treatment (control group)
Number of subjects: 54
Study 31112442 — intervention group
Group type: EXPERIMENTAL
Intervention: In-clinic CBT for anxiety
Number of subjects: 50
Study 31112442 — intervention group
Group type: COMPARATOR
Intervention: iGlebe (5 months online access)
Number of subjects: 50
Study 28219383 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, multidimensional transitional care package
Number of subjects: 0
Study 28219383 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25733246 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg
Number of subjects: 0
Study 25733246 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 0
Study 25733246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23858729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids
Number of subjects: 57
Study 23858729 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene receptor antagonists
Number of subjects: 57
Study 23858729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 21889250 — intervention group
Group type: COMPARATOR
Intervention: Dynamic control condition (focus on dynamic features of the task)
Number of subjects: 0
Study 21889250 — intervention group
Group type: COMPARATOR
Intervention: Spatial control condition (focus on visuomotor features of the task)
Number of subjects: 0
Study 19132857 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII with RT-CGM as an adjunct to SMBG (n = 14)
Number of subjects: 28
Study 19132857 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI) and self-monitoring of blood glucose (SMBG) (control arm)
Number of subjects: 28
Study 17262200 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn's disease
Number of subjects: 116